Source | Yaozhi.com Editor | Saipanlan
"2022 China Drug R&D Strength Ranking" is the 7th release since 2016. The series of lists consists of six major lists "2022 China Drug R&D Comprehensive Strength Ranking" (hereinafter referred to as the "General List"), "2022 China Chemical Drug R&D Strength Ranking" (hereinafter referred to as the "Chemical Drug List"), "2022 China Traditional Chinese Medicine R&D Strength Ranking" (hereinafter referred to as the "Chinese Medicine List"), "2022 China Biopharma R&D Strength Ranking" (hereinafter referred to as the "Biopharmaceutical List"), and "2022 China Pharmaceutical CRO Enterprises Top 20" (hereinafter referred to as the "Pharmaceutical CRO List"), and "2022 China Pharmaceutical CDMO Enterprises Top 20" (hereinafter referred to as the "Pharmaceutical CDMO List").
"2022 China Drug R&D Strength Ranking" 4 major lists were conducted by Yaozhi.com, the expert committee of the drug R&D Strength Ranking, and the organizing committee of the 2022 China Pharmaceutical R&D Innovation Summit on a comprehensive statistical analysis of a number of R&D related data such as the company's drug acceptance and approval status in 2021, the investment capital of pharmaceutical companies in R&D, drug clinical trials, patents and enterprise historical drug R&D rankings, which excludes the impact of market and sales layout on the company. (Please check the attachment at the end of the article: "2022 China Drug R&D Strength Ranking" Scoring Rules)
"2022 China Drug R&D Comprehensive Strength Ranking" Top 100 are Hengrui Medicine , Zhengdatianqing , and Fosun Pharma; among them, Hengrui Medicine has been the champion of the "General List" for the fifth year, and Zhengdatianqing and Fosun Pharma are firmly ranked second and third in comparison with 2021;
"2022 China Chemical Drug R&D Strength Ranking" is Hengrui Medicine, Zhengda Tianqing, and Qilu Pharmaceutical ; this is also the three consecutive years that Hengrui Medicine has won the "chemical drug list" title. Qilu Pharmaceutical has returned to the top three since 2019;
"2022 China Traditional Chinese Medicine R&D Strength Ranking" is Yiling Pharmaceutical, Kangyuan Pharmaceutical , and Tianshili Pharmaceutical. Among them, Yiling Pharmaceutical has ranked first on the "Traditional Medicine List" for the first time since the list was released in 2016;
"2022 China Biopharmaceutical R&D Strength Rankings Top 50", the top three are the same as last year, and are still Hengrui Medicine, Innobi , and Junshi Biologics .
"Top 20 Chinese Pharmaceutical CRO/CDMO Enterprises" are selected strictly based on 10 indicators including the company's annual total revenue (total operating income), annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, personnel scale, personnel scale growth, brand awareness, and leading segments, representing the highest level in the pharmaceutical CRO/CDMO industry.
"2022 Top 20 Chinese Pharmaceutical CRO Enterprises" WuXi AppTec, Kanglong Huacheng, Tiger Pharmaceutical and other companies were listed;
"2022 Top 20 Chinese Pharmaceutical CDMO Enterprises" WuXi Biologics, Kailaiying , Boteng Co., Ltd. and other companies were listed.
Attachment 1: "2022 China Drug R&D Strength Ranking" Scoring Rules
html ml31. Statistical rules of "2022 China Drug R&D Strength Ranking"
"2022 China Drug R&D Strength Ranking" consists of "2022 China Drug R&D Comprehensive Strength Ranking" (hereinafter referred to as the "General List"), and "2022 China Chemical Drug R&D Strength Ranking" (hereinafter referred to as the "Chemical Drug List"), "2022 China Traditional Chinese Medicine R&D Strength Ranking" (hereinafter referred to as the "Chinese Medicine List"), and "2022 China Biopharma R&D Strength Ranking" (hereinafter referred to as the "Biopharmaceutical List").
statistics mainly include: drug acceptance and approval scores in 2021, drug company R&D investment funds scores, drug clinical trial scores, patent scores and enterprise historical drug R&D ranking scores.
2. Calculation rules for each ranking
(I) Ranking Scoring Rules
This ranking Scoring Rules are formulated by the Expert Committee of the Drug R&D Strength Ranking and the Organizing Committee of the 2022 China Medical R&D Innovation Summit, and are calculated based on relevant data.
1. "Total List" scoring rules
"Total List" is calculated proportionally based on five parts of the drug acceptance and approval score in 2021, the drug R&D investment score, drug clinical trial score, patent score and enterprise historical drug R&D ranking score (2021).
The R&D investment situation is only for listed companies or companies that provide audit data, and companies that do not have R&D investment data will not calculate this item. The total score of enterprises without R&D investment data is calculated proportionally based on the four parts of the drug acceptance and approval score, drug clinical trial score, patent score and enterprise historical drug R&D ranking score (2021) (the proportion of each part is shown in Table 1).
Table 1 Score components and proportions of "Total List"
2. "Chemical Medicine List" Scoring Rules
"Chemical Medicine List" is calculated proportionally from the four parts of the drug acceptance and approval score in 2021, the drug R&D investment score, the drug clinical trial completion score and the enterprise historical drug R&D ranking score (2021).
The R&D investment situation is only for listed companies or companies that provide audit data, and companies that do not have R&D investment data will not calculate this item. The total score of enterprises without R&D investment data consists of three parts: drug acceptance and approval scores, drug clinical trial completion scores, and enterprise historical drug R&D ranking scores (2021) (the proportion of each part is shown in Table 2).
Table 2 Score components and ratios of "Chemical Medicine List"
3. "Bio Drug List" scoring rules
"Bio Drug List" scoring rules are the same as those of the "Chemical Medicine List" (the proportion of each part is shown in Table 3, for example).
Table 3 Score components and proportions of "Bio-medicine List"
4. "Traditional Medicine List" Scoring Rules
"Traditional Medicine List" is calculated proportionally from five parts: drug acceptance and approval scores, pharmaceutical companies' R&D investment funds scores, drug clinical trial completion scores, 2021 academic output scores and enterprise historical drug R&D ranking scores (2021, 2020)
Among them, since the difficulty of corporate traditional Chinese medicine research and development and the current number of corporate traditional Chinese medicine declarations and approvals is limited, the registration application situation alone cannot fully reflect the company's R&D situation. Therefore, this latest included the company's academic output scores in 2021; in addition, the R&D investment situation is only for listed companies or companies that provide audit data, and companies that do not have R&D investment data will not calculate this item. The total score of enterprises without R&D investment data consists of four parts: drug acceptance and approval scores, drug clinical trial completion scores, academic output scores in 2021 and enterprise historical drug R&D ranking scores (2021 and 2020) (the proportion of each part is shown in 4, for example).
Table 4 "Traditional Medicine List" Score Components and Proportion
Note: Among the historical ranking score items: China's drug R&D strength ranking score accounted for 6%, and China's drug R&D strength ranking score accounted for 4%;
(II) Special Note
1. Note on special bonus items
1 (1) 2021 National Intrinsic FDA, EU companies that apply for drugs and companies that have been approved for marketing or clinical practice will be given appropriate bonus points;
(2) Appropriate bonus points for major special projects, special approval varieties, and priority review varieties;
(3) Appropriate bonus points for domestic new drug research and development projects in 2021 (transaction amount of more than 100 million yuan) will be given appropriate bonus points;
(4) Registered clinical trials will be given appropriate bonus points for companies that have made actual progress in the year;
(5) National major science and technology awards.
2. Note on the weight of drug registration classification
When calculating the drug acceptance and approval scores in 2021, different weights are given to different drug registration classifications (such as chemical drug category 1, chemical drug category 2, etc.), to reflect the differences in drug research and development strength.
3. Description of the data source
data comes from the "Yaozhi Drug Registration and Acceptance Database". Enterprises include pharmaceutical companies, research institutes (excluding universities, hospitals) and other units. Among them, the acceptance situation (admission dates from January 1 to December 31, 2021) scores and approval status (status start dates from January 1 to December 31, 2021) scores are calculated by the "Yaozhi Drug Registration and Acceptance Database" data; the clinical trial registration completion score is calculated by the "China Clinical Trial Database" data; the patent score is calculated by the "Yaozhi Patent Connect" data; the R&D investment capital of pharmaceutical companies comes from the 2021 annual report data of major listed pharmaceutical companies, including a. Shanghai Stock Exchange, Shenzhen Securities, Hong Kong stock , New Third Board, GEM , US stock ; b. Listed companies that have issued prospectus announcements; c. Enterprises that actively provide audit reports (non-listed).
It is worth noting that this list is mainly based on the company's "2021 single-year indicators" and is based on the weight. In principle, it only represents the company's R&D strength and brand awareness in 2021. This list is the seventh release (released once a year). The Expert Committee of the Drug R&D Strength Ranking and the 2022 China Medical R&D Innovation Summit Organizing Committee adhere to the principles of professionalism, concentration, integrity and responsibility, and try to be fair and just as much as possible, but there will inevitably be any lack of scoring, so please forgive me.
Attachment 2: "2022 China Pharmaceutical CRO/CDMO Enterprises Top 20" Scoring Rules
This ranking list is divided into two major lists according to business direction: "2022 China Pharmaceutical CRO Enterprises Top 20" and "2022 China Pharmaceutical CDMO Enterprises Top 20". The
ranking score involves multiple indicators, including 10 indicators including the company's annual total revenue (total operating income), annual revenue growth (%), net profit, net profit growth (%), R&D investment, R&D investment growth (%), personnel scale, personnel scale growth (%), brand awareness (voting score), and leading sectors. Each indicator accounts for 10 indicators, as shown in the table below, listed companies directly call on annual report data, and non-listed companies submit data by enterprises and confirm by expert committees.
Data source: The data on this list is pharmaceutical CRO or CDMO business data, and does not include data on non-pharmaceutical and non-outsourcing services such as medical devices. Among them, listed companies use enterprise annual report data, and non-listed companies submit data by enterprises and confirm by the expert committee.
